Abstract | BACKGROUND AND PURPOSE: METHODS: Baseline demographics and interaction of treatment effects of rivaroxaban and warfarin among patients within East Asia and outside were assessed. RESULTS: A total of 932 (6.5%) ROCKET AF participants resided in East Asia. At baseline, East Asians had lower weight, creatinine clearance, and prior vitamin K antagonist use; higher prevalence of prior stroke; and less congestive heart failure and prior myocardial infarction than other participants. Despite higher absolute event rates for efficacy and safety outcomes in East Asians, the relative efficacy of rivaroxaban (20 mg once daily; 15 mg once daily for creatinine clearance of 30-49 mL/min) versus warfarin with respect to the primary efficacy end point ( stroke/systemic embolism) was consistent among East Asians and non-East Asians (interaction P=0.666). Relative event rates for the major or nonmajor clinically relevant bleeding in patients treated with rivaroxaban and warfarin were consistent among East Asians and non-East Asians (interaction P=0.867). CONCLUSIONS:
|
Authors | Ka Sing Lawrence Wong, Dai Yi Hu, Abraham Oomman, Ru-San Tan, Manesh R Patel, Daniel E Singer, Günter Breithardt, Kenneth W Mahaffey, Richard C Becker, Robert Califf, Keith A A Fox, Scott D Berkowitz, Werner Hacke, Graeme J Hankey, Executive Steering Committee and the ROCKET AF Study Investigators |
Journal | Stroke
(Stroke)
Vol. 45
Issue 6
Pg. 1739-47
(06 2014)
ISSN: 1524-4628 [Electronic] United States |
PMID | 24763930
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2014 American Heart Association, Inc. |
Chemical References |
- Anticoagulants
- Factor Xa Inhibitors
- Morpholines
- Thiophenes
- Vitamin K
- Warfarin
- Rivaroxaban
|
Topics |
- Aged
- Anticoagulants
(administration & dosage, adverse effects)
- Asian People
- Double-Blind Method
- Factor Xa Inhibitors
- Asia, Eastern
(epidemiology)
- Female
- Humans
- Male
- Morpholines
(administration & dosage, adverse effects)
- Risk Factors
- Rivaroxaban
- Stroke
(epidemiology, prevention & control)
- Thiophenes
(administration & dosage, adverse effects)
- Vitamin K
(antagonists & inhibitors)
- Warfarin
(administration & dosage, adverse effects)
|